What is HC Wainwright’s Estimate for AVBP FY2026 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for shares of ArriVent BioPharma in a research report issued on Tuesday, November 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($3.73) per share for the year, up from their prior estimate of ($4.06). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2026 earnings at ($0.90) EPS, Q1 2027 earnings at ($0.92) EPS, Q2 2027 earnings at ($0.94) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.98) EPS and FY2027 earnings at ($3.80) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $0.80 million.

Several other equities research analysts have also recently issued reports on the company. Citigroup reduced their target price on ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Thursday, October 15th. Oppenheimer reissued an “outperform” rating and set a $25.00 price target on shares of ArriVent BioPharma in a research note on Monday, October 26th. JonesTrading cut their price target on ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, October 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $29.00 price objective on shares of ArriVent BioPharma in a research note on Friday, October 16th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ArriVent BioPharma has an average rating of “Moderate Buy” and a consensus target price of $24.89.

ArriVent BioPharma Stock Up 0.1%

AVBP opened at $13.51 on Thursday. The company has a market capitalization of $698.78 million, a PE ratio of -3.75 and a beta of 1.66. The firm has a 50-day simple moving average of $22.07 and a two-hundred day simple moving average of $26.51. ArriVent BioPharma has a 52 week low of $11.36 and a 52 week high of $35.83.

Hedge Funds Weigh In On ArriVent BioPharma

Several institutional investors have recently bought and sold shares of AVBP. Hhlr Advisors LTD. purchased a new position in shares of ArriVent BioPharma in the 2nd quarter worth $136,498,000. BlackRock Inc. purchased a new stake in shares of ArriVent BioPharma during the 2nd quarter valued at about $112,919,000. General Catalyst Group Management LLC purchased a new stake in shares of ArriVent BioPharma during the 2nd quarter valued at about $51,929,000. Vivo Capital LLC purchased a new stake in shares of ArriVent BioPharma during the 1st quarter valued at about $20,438,000. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of ArriVent BioPharma by 390.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 246,606 shares of the company’s stock valued at $8,567,000 after acquiring an additional 196,354 shares during the last quarter. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.